Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04460911 · ClinicalTrials.gov registry record
Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.
A clinical trial, sponsored by Pfizer.
- Completed
- Registry status
- 317
- Enrollment target
NCT04460911 is a clinical trial that has completed, run by Pfizer. The registered enrollment target is 317 participants.
The verdict
NCT04460911 has completed, sponsored by Pfizer.
- COMPLETED
- Registry status
- 317 participants
- Enrollment target
Study Summary
By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of a large community oncology network in the United States.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 317 participants |
| Start Date | 2019-10-19 |
| Est. Completion | 2022-04-01 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04460911
The ClinicalTrials.gov registry entry for NCT04460911 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 317 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT04460911 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04460911 about?
NCT04460911 is a clinical study titled "Treatment Patterns and Clinical Outcomes Among Patients With HR+/HER2- mBC Receiving Palbociclib Combination Therapy in the US Community Oncology Setting.". By leveraging a community-based, cancer-specific electronic healthcare record for this study, we aim to understand treatment patterns and clinical outcomes among patients with HR+/HER2- mBC who received care within the context of a large community oncology network in the United States.
What is the current status of trial NCT04460911?
This trial is currently completed. The enrollment target is 317 participants. The study started on 2019-10-19. Estimated completion is 2022-04-01.
Who is sponsoring clinical trial NCT04460911?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.